RxDoctor Payments DataLook up a doctor →

Christopher Brown, MD

Cardiovascular Disease · Mobile, ALNPI 1982685640

Payments from drug & device makers

$1,390,166in general payments, 2019–2025

Across 332 payments — averaging $4187.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$716K
  • AstraZeneca$174K
  • Novartis$156K
  • Eli Lilly$154K
  • Boehringer Ingelheim International GmbH$46K
  • Bayer$43K
  • plus $102K from 9 others
$4,712in research payments, 2019–2025

Across 2 payments — averaging $2355.84 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$5K

General payments by program year

21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,390,166 in reported general payments places this provider in the 95th percentile of 292 cardiovascular disease providers in Alabama.

See all cardiovascular disease providers in Alabama

Medicare billing

Part B allowed, 2024
$456,302
Medicare patients
1,025
Services billed
4,394

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other cardiovascular disease in Mobile

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →